Clinical trials
Homologous Recombination Deficiency clinical trials
Below are recruiting homologous recombination deficiency clinical trials, each written for real people, not researchers. We’re tracking 16 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06095141RecruitingPhase 2/Phase 3
Cisplatin for pancreatic cancer with HRD
This trial tests the drug cisplatin in patients with advanced pancreatic cancer that has a specific DNA repair problem called homologous recombination deficiency (HRD). It may offer a new treatment option for those whose cancer has progressed after at least one prior chemotherapy.
ShanghaiAges 18–80 - NCT06525298RecruitingPhase 1/Phase 2
Study of EIS-12656 for solid tumors with DNA repair defects
This trial tests a new drug, EIS-12656, alone or with other treatments, for solid tumors that have specific DNA repair problems called homologous recombination deficiency. It may be an option if your cancer has not responded to prior treatments.
Houston, TexasAges 18 years+ - NCT03522064RecruitingPhase 2
HRD-positive advanced prostate cancer trial with androgen therapy and chemo
This Phase 2 study tests whether blocking male hormones (androgen therapy) plus the chemotherapy drug carboplatin can shrink advanced prostate cancer in men with specific DNA repair problems. It is for cases where prostate-specific antigen (PSA) is rising even though testosterone is already kept very low.
Sydney, New South WalesAges 18 years+ - NCT06177171RecruitingPhase 1
Olaparib and ASTX727 for DNA repair-deficient cancers
This trial tests a combination of two drugs—olaparib (a PARP inhibitor) and ASTX727 (a DNA hypomethylating agent)—for people whose cancers have a specific DNA repair flaw. The goal is to see if this combination can shrink tumors or slow their growth.
San Francisco, CaliforniaAges 18 years+ - NCT04892693RecruitingPhase 2
Talazoparib for advanced breast cancer with DNA repair defects
This trial studies talazoparib (a targeted pill) in people with advanced breast cancer whose tumors have problems repairing certain DNA damage. If your tumor has these specific “DNA repair” defects, the medicine may work better and stop the cancer from growing.
SeoulAges 19 years+ - NCT07446855RecruitingPhase 1/Phase 2
Study of AZD4956 for advanced solid tumors with DNA repair problems
This trial tests a new drug called AZD4956, alone or with other cancer medicines, for people with advanced solid tumors that have certain DNA repair problems (called homologous recombination deficiency). It may be an option if you have breast, ovarian, prostate, or pancreatic cancer with a specific gene change, and you have or haven't had previous PARP inhibitor treatment.
New York, New YorkAges 18–130 - NCT06545942RecruitingPhase 1
Studying MOMA-313 for advanced or metastatic solid tumors
This trial tests a new oral drug, MOMA-313, alone or with another drug (olaparib), in people whose cancer has a specific DNA repair problem (HR-deficient mutation). It aims to see if the drug can shrink tumors or slow their growth.
Goodyear, ArizonaAges 18 years+ - NCT06458712RecruitingPhase 1
Testing a new drug for advanced cancers with gene changes
This study tests a new oral drug, DSB2455, for people with advanced breast, prostate, ovarian, or pancreatic cancers that have certain gene changes. It aims to see if the drug is safe and whether it helps shrink or control the cancer.
New Haven, ConnecticutAges 18 years+ - NCT04503265RecruitingPhase 1/Phase 2
AMXI-5001 study for advanced cancers that won’t respond
This Phase 1/2 trial tests AMXI-5001 in people with advanced cancers that have progressed or stopped responding to standard treatments. It’s mainly designed to find the safest dose and see early signs the treatment might work.
Los Angeles, CaliforniaAges 18 years+ - NCT04515836RecruitingPhase 2
Olaparib for HRD malignant mesothelioma after platinum chemotherapy
This trial tests whether olaparib (a cancer medicine) can help control malignant mesothelioma that has specific DNA changes. You must have already had platinum chemotherapy and your cancer must be “platinum-sensitive,” plus your tumor (or family/genetic cells) must show certain gene problems.
Chicago, IllinoisAges 18 years+ - NCT04890613RecruitingPhase 1
CX-5461 for cancers with BRCA or HRD gene changes
This Phase 1 trial tests CX-5461, a new cancer medicine, in people with certain solid tumors that have BRCA1/2 or related “HRD” gene mutations. The goal is to find out how the drug works, what dose is tolerable, and whether it can help shrink tumors.
Santa Monica, CaliforniaAges 18 years+ - NCT06827353Recruiting
Comparing two maintenance drugs for ovarian cancer without DNA repair defects
This study compares two maintenance drugs (niraparib vs. bevacizumab) for people with advanced ovarian cancer who do not have certain DNA repair issues (BRCA mutation or HRD). It aims to see which drug works better to keep cancer from coming back.
Nîmes, OccitanieAges 18 years+ - NCT07472140RecruitingPhase 2/Phase 3
PARP inhibitor with or without anti-angiogenesis drug for ovarian cancer
This trial tests whether adding a drug that blocks blood vessel growth (angiogenesis inhibitor) to a PARP inhibitor works better than the PARP inhibitor alone for ovarian, fallopian-tube, or peritoneal cancers that have a specific DNA repair problem called HRD. It aims to find a more effective treatment for people with these cancers.
Minsk, LesnoyAges 18–75 - NCT06504147RecruitingPhase 2
Radspherin for ovarian cancer with peritoneal spread
This trial tests a radioactive treatment called Radspherin given during surgery for advanced ovarian cancer that has spread to the lining of the abdomen. It is for people whose tumors are HR proficient (a specific genetic type) and who have already had chemotherapy before surgery.
Tampa, FloridaAges 18 years+ - NCT06836219Recruiting
Study of treatment outcomes based on HRD status in advanced ovarian cancer
This study looks at how women with advanced ovarian cancer respond to treatments based on whether their tumors have a specific DNA repair problem called homologous recombination deficiency (HRD). It aims to understand which treatments work best for different HRD test results.
Bari, BAAges 18 years+ - NCT05466786Recruiting
Testing gene changes and DNA damage in HER2-low breast cancer
This trial studies breast cancer tumors to see how specific gene changes and DNA damage patterns relate to the cancer in people with HER2-low disease. It may help doctors better predict which patients could benefit from treatments that target these pathways.
Guangzhou, GuangdongAges 18–70
Hear when a new Homologous Recombination Deficiency trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for homologous recombination deficiency?
- Yes. Clin2 currently lists 16 recruiting homologous recombination deficiency studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a homologous recombination deficiency trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a homologous recombination deficiency trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.